Mervyn Turner had over 25 years of experience at Merck Research Laboratories in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years he was head of world-wide licensing and external research at Merck, during a period of rapid expansion in Merck’s partnering activities. He became Merck’s first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011.
He is currently an advisor to Bay City Capital in San Francisco, and also operates his own consulting business. He serves on the board of a private Australian biotech company, EnGeneIC. He is also on the board of Pharmakea, based in San Diego. He also serves as an advisor to Bridge Medicines, based in New York City. In addition to his work in the U.S. biotech industry, he served on the Steering Committee of the Wellcome Trust’s “Seeding Drug Discovery” program in London, and also served on the Scientific Advisory Board for the Drugs for Neglected Diseases initiative. He is currently a Senior Healthcare Advisor to Lazard, based in New York.